Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Adenocarcinoma × Lead × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2 Thrombophilia 1 Rectal Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Gastrointestinal Stromal Tumors 1 EGFR-Mutant Lung Cancer 1 Deglutition Disorders 1 Communication Disorders 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Pancreatic Ductal 1 Carcinoma 1 Brain Neoplasms 1 Blood Coagulation Disorders 1 Adenocarcinoma 1

Interventions

Gemcitabine 26 Fluorouracil 23 Oxaliplatin 19 Cisplatin 18 Leucovorin 15 Bevacizumab 14 Paclitaxel 12 130-nm albumin-bound paclitaxel 12 Capecitabine 11 Docetaxel 10 Albumin-Bound Paclitaxel 10 Irinotecan 9 Carboplatin 9 pembrolizumab 6 Radiotherapy 6 Pemetrexed 6 Nivolumab 6 Cyclophosphamide 6 Ramucirumab 5 Erlotinib Hydrochloride 5 Trastuzumab 4 Everolimus 4 Cetuximab 4 vandetanib 3 trastuzumab deruxtecan 3 sargramostim 3 folfirinox 3 Sorafenib 3 Ipilimumab 3 Gefitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡